Jump to content
RemedySpot.com

Re: Nebido - future market leader?

Rate this topic


Guest guest

Recommended Posts

I have not used Nebido, but I have heard about it from men in Europe, and there

seems to

be a consensis that it does not last as long as it is advertised to. The men

that I have

coresponded with said that the nebido injections are only lasting three months

before they

start to fall below targeted levels,

Second, Nebido is merely testosterone undecanote, and this particular

testosterone ester

has been around for a long time. The pill form of testosterone undecanote is

called

andriol and it has been around for close to 20 yrs or more.

I see the real future of treating secondary hypogonadism as a diabetic like pump

that

administers LH and FSH in such away to simulate the pituitary's natural cycles

and normal

HPTA function

>

> Was reading a book on hypogonadism - Jockenhovel, F., and Schubert, M.

> (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty recent

> and it stated Nebido will be the standard treatment for hypogonadism

> because it has favourable effects with regards to libido, bones and

> muscle mass, low incidence of side effects and is more stable therefore

> avoiding the peaks and troughs normally seen with shorter acting

> injectables.

>

> Also more acceptable to users because only needs to be injected 4/5

> times a year as opposed to 26-52 times - quite a difference. Probably

> its biggest selling point!

>

> However since its market launch in 2004 in Europe it does not seem to

> be the market leader and I do not hear of many people using it. Anyone

> know why this is?

>

> Anyone got good/bad experiences on it they can share?

>

> I know the FDA is currently working with Indevus Pharmaceuticals

> (license for Nebido bought from Bayer Schering Pharma) and has been

> unhappy with some respiratory side effects in few users (at least 1/100

> people) and therefore wants the company to suggest and implement ways

> to reduce these effects before an FDA license will be granted for US

> market release.

>

> Will be interesting to see how this one develops.

>

Link to comment
Share on other sites

It's great for raising your libido. I am horny 24/7 on it! Pity I don't have the

energy or indeed the men with whom to share it!

I'm not so sure about the bones. Since starting on Nebido in 2004 I have

developed Osteoporosis, Sero negative Arthritis and a mysterious muscle wasting

condition. I know that Osteoporosis and Arthritis are common in XXY's -

Klinefelters Syndrome, but I reckon that the high level of Testo in my system

may be the cause of the muscle waste. I'm not exactly sure what my level of

Testo is, but I do know that it's around 8 times higher than the average XY

male, bearing in mind that Nebido contains 1000mg in a 4ml solution. You are

also correct about it levelling out the Peaks and Troughs associated with other

forms of treatment. I spent nearly 30 years of my life suffering from

depression. The latter 10 years I was on the Testo pellets, sub-cutaneously

implanted every 3 months. I then spent the next 5 years trying out different

injectable doses and frequencies. I also tried Androgel. The Peaks and Troughs

were dreadful. These disappeared completely once I

went onto Nebido. For those of us with Klinefelters, I find that it does trail

off somewhat toward the end of the 12 week cycle and for about 2 - 3 weeks

before the next shot, I often have great difficulty staying awake. The flipside

of that is the difficulty I have getting to sleep throughout the 2nd to 5th week

following the shot.

It also may be responsible (or rather TRT in general) for making my skin itch,

but try telling that to a medic, Most just dismiss it out of hand.

Getting the shot itself I find quite painful. It's not painful at the injection

site, but I always get a dull pain travelling down my leg into my toes and that

usually remains in my foot for several hours. The shot doesn't bother me, but it

does seem to bother the nurses who administer it as it takes a while to inject

it because of the thick carrier oil (Castor Oil).

However speaking for myself, it's by far the best form of TRT I've ever

experienced and I've been getting T one way or another for 21 years. Like any

drug it does have good and bad side effects. I think I have tried all forms of

delivery throughout the 21 years since dx in 1987.

Steph Glasgow

From: chrisdl2008 <chrisdl2008@...>

Subject: Nebido - future market leader?

Date: Thursday, 11 December, 2008, 9:12 PM

Was reading a book on hypogonadism - Jockenhovel, F., and Schubert, M.

(2007). `Male hypogonadism'. Uni-Med Science.- which is pretty recent

and it stated Nebido will be the standard treatment for hypogonadism

because it has favourable effects with regards to libido, bones and

muscle mass, low incidence of side effects and is more stable therefore

avoiding the peaks and troughs normally seen with shorter acting

injectables.

Also more acceptable to users because only needs to be injected 4/5

times a year as opposed to 26-52 times - quite a difference. Probably

its biggest selling point!

However since its market launch in 2004 in Europe it does not seem to

be the market leader and I do not hear of many people using it. Anyone

know why this is?

Anyone got good/bad experiences on it they can share?

I know the FDA is currently working with Indevus Pharmaceuticals

(license for Nebido bought from Bayer Schering Pharma) and has been

unhappy with some respiratory side effects in few users (at least 1/100

people) and therefore wants the company to suggest and implement ways

to reduce these effects before an FDA license will be granted for US

market release.

Will be interesting to see how this one develops.

------------------------------------

Link to comment
Share on other sites

As far as I am aware it's supposed to last only 3 months. Mine are every 12

weeks.

Steph

From: sbryant511 <sbryant511@...>

Subject: Re: Nebido - future market leader?

Date: Thursday, 11 December, 2008, 10:56 PM

I have not used Nebido, but I have heard about it from men in Europe, and there

seems to

be a consensis that it does not last as long as it is advertised to. The men

that I have

coresponded with said that the nebido injections are only lasting three months

before they

start to fall below targeted levels,

Second, Nebido is merely testosterone undecanote, and this particular

testosterone ester

has been around for a long time. The pill form of testosterone undecanote is

called

andriol and it has been around for close to 20 yrs or more.

I see the real future of treating secondary hypogonadism as a diabetic like

pump that

administers LH and FSH in such away to simulate the pituitary's natural

cycles and normal

HPTA function

>

> Was reading a book on hypogonadism - Jockenhovel, F., and Schubert, M.

> (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty recent

> and it stated Nebido will be the standard treatment for hypogonadism

> because it has favourable effects with regards to libido, bones and

> muscle mass, low incidence of side effects and is more stable therefore

> avoiding the peaks and troughs normally seen with shorter acting

> injectables.

>

> Also more acceptable to users because only needs to be injected 4/5

> times a year as opposed to 26-52 times - quite a difference. Probably

> its biggest selling point!

>

> However since its market launch in 2004 in Europe it does not seem to

> be the market leader and I do not hear of many people using it. Anyone

> know why this is?

>

> Anyone got good/bad experiences on it they can share?

>

> I know the FDA is currently working with Indevus Pharmaceuticals

> (license for Nebido bought from Bayer Schering Pharma) and has been

> unhappy with some respiratory side effects in few users (at least 1/100

> people) and therefore wants the company to suggest and implement ways

> to reduce these effects before an FDA license will be granted for US

> market release.

>

> Will be interesting to see how this one develops.

>

------------------------------------

Link to comment
Share on other sites

All the guys I have spoken too have done very poorly on Nebido and changed to

other treatments they have felt better on. Just goes to show you it is a case

of horses for courses and what works for one person doesn't work for another and

vice versa.

The dosage of Nebido is HUGE and I feel this is to benefit the treating

clinician not the patient.

You get a huge overdose of testosterone at the peak and that results in

insomnia. Even though undecanoate doesn't readily convert to estradiol, the

size of the dose often results in high E2 levels. That can mean itching skin,

gynecomastia and emotional issues especially neaer to the next dose with low

testosterone levels.

I do not think it will succeed in the US where patient choice is the key issue.

Not enough patients will like it.

> From: chrisdl2008 <chrisdl2008@...>

> Subject: Nebido - future market leader?

>

> Date: Thursday, 11 December, 2008, 9:12 PM

>

> Was reading a book on hypogonadism - Jockenhovel, F., and Schubert, M.

> (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty recent

> and it stated Nebido will be the standard treatment for hypogonadism

> because it has favourable effects with regards to libido, bones and

> muscle mass, low incidence of side effects and is more stable therefore

> avoiding the peaks and troughs normally seen with shorter acting

> injectables.

>

> Also more acceptable to users because only needs to be injected 4/5

> times a year as opposed to 26-52 times - quite a difference. Probably

> its biggest selling point!

>

> However since its market launch in 2004 in Europe it does not seem to

> be the market leader and I do not hear of many people using it. Anyone

> know why this is?

>

> Anyone got good/bad experiences on it they can share?

>

> I know the FDA is currently working with Indevus Pharmaceuticals

> (license for Nebido bought from Bayer Schering Pharma) and has been

> unhappy with some respiratory side effects in few users (at least 1/100

> people) and therefore wants the company to suggest and implement ways

> to reduce these effects before an FDA license will be granted for US

> market release.

>

> Will be interesting to see how this one develops.

>

>

>

> ------------------------------------

>

>

Link to comment
Share on other sites

In late 05 or early 06 I was adked if I would like to be in the

Nebido trial. I almost got in but my history of Sleep Apena kept me

out.

After the trial was over I asked the doctor about the results. He

said that it did not work as expected and that it probally would not

reach market in the US.

Jack

> > From: chrisdl2008 <chrisdl2008@>

> > Subject: Nebido - future market leader?

> >

> > Date: Thursday, 11 December, 2008, 9:12 PM

> >

> > Was reading a book on hypogonadism - Jockenhovel, F., and

Schubert, M.

> > (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty

recent

> > and it stated Nebido will be the standard treatment for

hypogonadism

> > because it has favourable effects with regards to libido, bones

and

> > muscle mass, low incidence of side effects and is more stable

therefore

> > avoiding the peaks and troughs normally seen with shorter acting

> > injectables.

> >

> > Also more acceptable to users because only needs to be injected

4/5

> > times a year as opposed to 26-52 times - quite a difference.

Probably

> > its biggest selling point!

> >

> > However since its market launch in 2004 in Europe it does not

seem to

> > be the market leader and I do not hear of many people using it.

Anyone

> > know why this is?

> >

> > Anyone got good/bad experiences on it they can share?

> >

> > I know the FDA is currently working with Indevus Pharmaceuticals

> > (license for Nebido bought from Bayer Schering Pharma) and has

been

> > unhappy with some respiratory side effects in few users (at least

1/100

> > people) and therefore wants the company to suggest and implement

ways

> > to reduce these effects before an FDA license will be granted for

US

> > market release.

> >

> > Will be interesting to see how this one develops.

> >

> >

> >

> > ------------------------------------

> >

> >

Link to comment
Share on other sites

Based on what I have read about Nebido I wouldn't let them inject my dog

with this stuff.

Neil

JACKPINNER wrote:

>

> In late 05 or early 06 I was adked if I would like to be in the

> Nebido trial. I almost got in but my history of Sleep Apena kept me

> out.

> After the trial was over I asked the doctor about the results. He

> said that it did not work as expected and that it probally would not

> reach market in the US.

> Jack

>

> > > From: chrisdl2008 <chrisdl2008@>

> > > Subject: Nebido - future market leader?

> > >

> <mailto: %40>

> > > Date: Thursday, 11 December, 2008, 9:12 PM

> > >

> > > Was reading a book on hypogonadism - Jockenhovel, F., and

> Schubert, M.

> > > (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty

> recent

> > > and it stated Nebido will be the standard treatment for

> hypogonadism

> > > because it has favourable effects with regards to libido, bones

> and

> > > muscle mass, low incidence of side effects and is more stable

> therefore

> > > avoiding the peaks and troughs normally seen with shorter acting

> > > injectables.

> > >

> > > Also more acceptable to users because only needs to be injected

> 4/5

> > > times a year as opposed to 26-52 times - quite a difference.

> Probably

> > > its biggest selling point!

> > >

> > > However since its market launch in 2004 in Europe it does not

> seem to

> > > be the market leader and I do not hear of many people using it.

> Anyone

> > > know why this is?

> > >

> > > Anyone got good/bad experiences on it they can share?

> > >

> > > I know the FDA is currently working with Indevus Pharmaceuticals

> > > (license for Nebido bought from Bayer Schering Pharma) and has

> been

> > > unhappy with some respiratory side effects in few users (at least

> 1/100

> > > people) and therefore wants the company to suggest and implement

> ways

> > > to reduce these effects before an FDA license will be granted for

> US

> > > market release.

> > >

> > > Will be interesting to see how this one develops.

> > >

> > >

> > >

> > > ------------------------------------

> > >

> > >

Link to comment
Share on other sites

I for one am glad Nebido exists. It's the only method that does not

produce the highs and lows I experienced for 15 years before going

onto Nebido.

Steph (Glasgow)

> > > > From: chrisdl2008 <chrisdl2008@>

> > > > Subject: Nebido - future market leader?

> > > >

> > <mailto: %40>

> > > > Date: Thursday, 11 December, 2008, 9:12 PM

> > > >

> > > > Was reading a book on hypogonadism - Jockenhovel, F., and

> > Schubert, M.

> > > > (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty

> > recent

> > > > and it stated Nebido will be the standard treatment for

> > hypogonadism

> > > > because it has favourable effects with regards to libido, bones

> > and

> > > > muscle mass, low incidence of side effects and is more stable

> > therefore

> > > > avoiding the peaks and troughs normally seen with shorter acting

> > > > injectables.

> > > >

> > > > Also more acceptable to users because only needs to be injected

> > 4/5

> > > > times a year as opposed to 26-52 times - quite a difference.

> > Probably

> > > > its biggest selling point!

> > > >

> > > > However since its market launch in 2004 in Europe it does not

> > seem to

> > > > be the market leader and I do not hear of many people using it.

> > Anyone

> > > > know why this is?

> > > >

> > > > Anyone got good/bad experiences on it they can share?

> > > >

> > > > I know the FDA is currently working with Indevus Pharmaceuticals

> > > > (license for Nebido bought from Bayer Schering Pharma) and has

> > been

> > > > unhappy with some respiratory side effects in few users (at least

> > 1/100

> > > > people) and therefore wants the company to suggest and implement

> > ways

> > > > to reduce these effects before an FDA license will be granted for

> > US

> > > > market release.

> > > >

> > > > Will be interesting to see how this one develops.

> > > >

> > > >

> > > >

> > > > ------------------------------------

> > > >

> > > >

Link to comment
Share on other sites

Actually to be fair the muscle waste and arthritis probably started

when I was in my early teens. Slow progression has taken it's toll and

now I am a wheelchair user because of it.

Nebido does work for me. As for it causing insomnia, I've had insomnia

since starting on TRT 22 years ago and that was only 150mg every 3

weeks! So, I am not sure that Nebido causes insomnia per se.

It certainly doesn't help. However this bad side effect outdoes the

benefits such as stable mood, motivation, concentration to name but a

few. Too tired to think. As I said in a previous post, Chronic fatigue

is one of the conditions associated with Klinefelters. Over- tiredness

can also cause insomnia.

Steph (Glasgow)

> > From: chrisdl2008 <chrisdl2008@>

> > Subject: Nebido - future market leader?

> >

> > Date: Thursday, 11 December, 2008, 9:12 PM

> >

> > Was reading a book on hypogonadism - Jockenhovel, F., and

Schubert, M.

> > (2007). `Male hypogonadism'. Uni-Med Science.- which is pretty recent

> > and it stated Nebido will be the standard treatment for hypogonadism

> > because it has favourable effects with regards to libido, bones and

> > muscle mass, low incidence of side effects and is more stable

therefore

> > avoiding the peaks and troughs normally seen with shorter acting

> > injectables.

> >

> > Also more acceptable to users because only needs to be injected 4/5

> > times a year as opposed to 26-52 times - quite a difference. Probably

> > its biggest selling point!

> >

> > However since its market launch in 2004 in Europe it does not seem to

> > be the market leader and I do not hear of many people using it.

Anyone

> > know why this is?

> >

> > Anyone got good/bad experiences on it they can share?

> >

> > I know the FDA is currently working with Indevus Pharmaceuticals

> > (license for Nebido bought from Bayer Schering Pharma) and has been

> > unhappy with some respiratory side effects in few users (at least

1/100

> > people) and therefore wants the company to suggest and implement ways

> > to reduce these effects before an FDA license will be granted for US

> > market release.

> >

> > Will be interesting to see how this one develops.

> >

> >

> >

> > ------------------------------------

> >

> >

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...